Lupin launches generic hypertension drug in US market
The company said it has introduced the product after getting approval from the US Food and Drug Administration.
According to IQVIA MAT July 2022 sales data, Sildenafil for Oral Suspension had estimated annual sales of USD 64 million in the US. Shares of Lupin on Thursday closed 2.46 per cent down at Rs 654.00 apiece on the BSE.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)